Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Eder

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumorsJeffrey G Supko, Joseph P Eder, David P Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumorsAnna Berkenblit, Joseph P Eder, David P Ryan, et al.
The Oncologist|May 2, 2007
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumorsDirk Strumberg, Jeffrey W Clark, Ahmad Awada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposideC Wheeler, M Strawderman, L Ayash, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patientsJ P Eder, A Elias, T C Shea, et al.
Contributions to Nephrology|January 1, 1991
Erythropoietin gene regulation: from the laboratory to the bedsideM A Goldberg, C C Gaut, L Schapira, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|April 11, 2009
A two-step method to covalently bind biomolecules to group-IV semiconductors: Si(111)/1,2-epoxy-9-decene/esteraseClaire Jeanquartier, Gerburg Schider, Sabine Feichtenhofer, et al.
Journal for Immunotherapy of Cancer|August 27, 2020
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumorsAung Naing, Joseph P Eder, Sarina A Piha-Paul, et al.
Archives of Dermatology|June 1, 1988
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow supportT C Shea, K H Antman, J P Eder, et al.
Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society|January 30, 2018
Bone mineral density and the 570A>T polymorphism of the bone morphogenetic protein 2 (BMP2) gene in patients with inflammatory bowel disease: a cross-sectional studyI Krela-Kazmierczak, A Wawrzyniak, A Szymczak, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumorsJeffrey G Supko, Joseph P Eder, David P Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumorsAnna Berkenblit, Joseph P Eder, David P Ryan, et al.
The Oncologist|May 2, 2007
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumorsDirk Strumberg, Jeffrey W Clark, Ahmad Awada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposideC Wheeler, M Strawderman, L Ayash, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patientsJ P Eder, A Elias, T C Shea, et al.
Contributions to Nephrology|January 1, 1991
Erythropoietin gene regulation: from the laboratory to the bedsideM A Goldberg, C C Gaut, L Schapira, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|April 11, 2009
A two-step method to covalently bind biomolecules to group-IV semiconductors: Si(111)/1,2-epoxy-9-decene/esteraseClaire Jeanquartier, Gerburg Schider, Sabine Feichtenhofer, et al.
Journal for Immunotherapy of Cancer|August 27, 2020
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumorsAung Naing, Joseph P Eder, Sarina A Piha-Paul, et al.
Archives of Dermatology|June 1, 1988
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow supportT C Shea, K H Antman, J P Eder, et al.
Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society|January 30, 2018
Bone mineral density and the 570A>T polymorphism of the bone morphogenetic protein 2 (BMP2) gene in patients with inflammatory bowel disease: a cross-sectional studyI Krela-Kazmierczak, A Wawrzyniak, A Szymczak, et al.
Pageof 12